OBI Pharma Granted FDA Orphan Drug Designation for the Treatment of Pancreatic Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999
First Orphan Drug Designation for OBI-999, a novel first-in-class Antibody-Drug Conjugate targeting Globo H, a glycolipid antigen found on multiple tumor types
TAIPEI, Taiwan, Dec. 26, 2019 -- (Healthcare Sales & Marketing Network) -- OBI Pharma, Inc.,... Biopharmaceuticals, Oncology, FDA OBI Pharma, Globo H, Pancreatic Cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Therapy | Marketing | Pancreas | Pancreatic Cancer | Pharmaceuticals | Taiwan Health